{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:55:00Z","timestamp":1792018500238,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T00:00:00Z","timestamp":1542931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,5,1]]},"DOI":"10.1007\/s40262-018-0721-y","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T02:13:31Z","timestamp":1542939211000},"page":"673-683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials"],"prefix":"10.1007","volume":"58","clinical-trial-number":[{"clinical-trial-number":"nct01856218","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02418455","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02230566","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yulan","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"McKeever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,23]]},"reference":[{"key":"721_CR1","volume-title":"The metabolic and molecular bases of inherited disease","author":"E Neufeld","year":"2001","unstructured":"Neufeld E, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. New York: McGraw-Hill; 2001."},{"key":"721_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0022-3476(73)80162-3","volume":"82","author":"WS Sly","year":"1973","unstructured":"Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr. 1973;82:249\u201357.","journal-title":"J Pediatr"},{"key":"721_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","volume":"53","author":"AM Montano","year":"2016","unstructured":"Montano AM, Lock-Hock N, Steiner RD, Graham BH, Szlago M, Greenstein R, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. 2016;53:403\u201318.","journal-title":"J Med Genet"},{"key":"721_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533\u20139.","journal-title":"J Pediatr"},{"key":"721_CR5","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1056\/NEJM200101183440304","volume":"344","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001;344:182\u20138.","journal-title":"N Engl J Med"},{"key":"721_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006;8:465\u201373.","journal-title":"Genet Med"},{"key":"721_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke LA, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J Pediatr. 2004;144:581\u20138.","journal-title":"J Pediatr"},{"key":"721_CR8","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1172\/JCI1773","volume":"101","author":"LH O\u2019Connor","year":"1998","unstructured":"O\u2019Connor LH, Erway LC, Vogler CA, Sly WS, Nicholes A, Grubb J, et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J Clin Investig. 1998;101:1394\u2013400.","journal-title":"J Clin Investig"},{"key":"721_CR9","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1023\/A:1005423222927","volume":"21","author":"C Vogler","year":"1998","unstructured":"Vogler C, Sands MS, Galvin N, Levy B, Thorpe C, Barker J, et al. Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease. J Inherit Metab Dis. 1998;21:575\u201386.","journal-title":"J Inherit Metab Dis"},{"key":"721_CR10","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1203\/00006450-199606000-00019","volume":"39","author":"C Vogler","year":"1996","unstructured":"Vogler C, Sands MS, Levy B, Galvin N, Birkenmeier EH, Sly WS. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr Res. 1996;39:1050\u20134.","journal-title":"Pediatr Res"},{"key":"721_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ymgme.2014.10.017","volume":"114","author":"JE Fox","year":"2015","unstructured":"Fox JE, Volpe L, Bullaro J, Kakkis ED, Sly WS. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab. 2015;114:203\u20138.","journal-title":"Mol Genet Metab"},{"key":"721_CR12","unstructured":"Ultragenyx Pharmaceutical Inc. MEPSEVIITM (vestronidase alfa-vjbk) prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761047s000lbl.pdf. Accessed 25 Apr 2018."},{"key":"721_CR13","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.ymgme.2016.11.144","volume":"120","author":"P Harmatz","year":"2017","unstructured":"Harmatz P, Whitley CB, Wang RY, Bauer M, Songe W, Jacobs K, et al. A novel, randomized, placebo-controlled, blind-start, single-crossover phase 3 study to assess the efficacy and safety of UX003 (rhGUS) enzyme replacement therapy in patients with MPS VII. Mol Genet Metab. 2017;120:S63.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"721_CR14","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.ymgme.2018.02.006","volume":"123","author":"P Harmatz","year":"2018","unstructured":"Harmatz P, Whitley CB, Wang RY, Bauer M, Song W, Haller C, et al. A novel Blind Start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. Mol Genet Metab. 2018;123(4):488\u201394.","journal-title":"Mol Genet Metab"},{"key":"721_CR15","unstructured":"BioMarin. NAGLAZYME\u00ae (galsulfase) prescribing information. 2013. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125117s111lbl.pdf. Accessed 19 Dec 2017."},{"key":"721_CR16","unstructured":"BioMarin\/Genzyme LLC. ALDURAZYME\u00ae prescribing information. 2013. https:\/\/www.aldurazyme.com\/patients.aspx. Accessed 19 Dec 2017."},{"key":"721_CR17","unstructured":"Shire Human Genetic Therapies I. ELAPRASE\u00ae (idursulfase) prescribing information. 2013. http:\/\/pi.shirecontent.com\/PI\/PDFs\/Elaprase_USA_ENG.pdf. Accessed 19 Dec 2017."},{"key":"721_CR18","unstructured":"US Food and Drug Adminstration. Laronidase for the treatment of mucopolysaccharidosis I; Clinical review (Advisory Committee Briefing Document). 2002. https:\/\/web.archive.org\/web\/20170114035825\/http:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/HowDrugsareDevelopedandApproved\/ApprovalApplications\/TherapeuticBiologicApplications\/ucm083695.pdf. Accessed 14 Nov 2018."},{"key":"721_CR19","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1172\/JCI118617","volume":"97","author":"AC Crawley","year":"1996","unstructured":"Crawley AC, Brooks DA, Muller VJ, Petersen BA, Isaac EL, Bielicki J, et al. Enzyme replacement therapy in a feline model of Maroteaux\u2013Lamy syndrome. J Clin Investig. 1996;97:1864\u201373.","journal-title":"J Clin Investig"},{"key":"721_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s40262-014-0173-y","volume":"53","author":"Y Qi","year":"2014","unstructured":"Qi Y, Musson DG, Schweighardt B, Tompkins T, Jesaitis L, Shaywitz AJ, et al. Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome. Clin Pharmacokinet. 2014;53:1137\u201347.","journal-title":"Clin Pharmacokinet"},{"key":"721_CR21","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/npjamd.2016.14","volume":"2","author":"I Seim","year":"2016","unstructured":"Seim I, Ma S, Gladyshev VN. Gene expression signatures of human cell and tissue longevity. NPJ Aging Mech Dis. 2016;2:16014.","journal-title":"NPJ Aging Mech Dis"},{"issue":"447","key":"721_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/08035320510028139","volume":"94","author":"P Harmatz","year":"2005","unstructured":"Harmatz P, Kramer WG, Hopwood JJ, Simon J, Butensky E, Mucopolysaccharidosis VI Study Group, et al. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux\u2013Lamy syndrome): a phase I\/II study. Acta Paediatr Suppl. 2005;94(447):61\u20138.","journal-title":"Acta Paediatr Suppl"},{"key":"721_CR23","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.clinthera.2014.11.005","volume":"37","author":"B Schweighardt","year":"2015","unstructured":"Schweighardt B, TompkinsT Lau K, Jesaitis L, Qi Y, et al. Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial. Clin Ther. 2015;37:1012\u201321.","journal-title":"Clin Ther"},{"issue":"3","key":"721_CR24","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1086\/318809","volume":"68","author":"CM Eng","year":"2001","unstructured":"Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, et al. A phase 1\/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet. 2001;68(3):711\u201322.","journal-title":"Am J Hum Genet"}],"updated-by":[{"DOI":"10.1007\/s40262-018-0726-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T00:00:00Z","timestamp":1543881600000}}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0721-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-018-0721-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0721-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:27:13Z","timestamp":1628616433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-018-0721-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,23]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,1]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0721-y","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40262-018-0726-6","asserted-by":"object"}]},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,23]]},"assertion":[{"value":"23 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"These studies were funded by Ultragenyx Pharmaceutical Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Study protocols for all procedures performed in studies involving human participants were reviewed and approved by Institutional Review Boards at each investigational site, and conducted in accordance with principles in the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Yulan Qi, Wenjie Song, and Christine Haller were employees of Ultragenyx Pharmaceutical Inc. at the time of the study. Kathleen McKeever, Julie Taylor, and Jack Shi are employees of Ultragenyx Pharmaceutical Inc. Simon A. Jones has been an investigator and consultant for Ultragenyx Pharmaceutical Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Each participant or his\/her legally authorized representative provided written informed consent before entering the study, in compliance with the applicable local regulations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}